At a Glance
| Property | Value |
|---|---|
| Evidence Level | Strong to Moderate (well-validated markers, established clinical utility) |
| Primary Use | Expanding standard blood work to detect early dysfunction |
| Key Mechanism | Identifying metabolic, inflammatory, and immune markers that standard panels omit |
The Standard Panel Is Not Enough
Your annual checkup blood work typically includes a CBC (complete blood count), CMP (comprehensive metabolic panel), and maybe a lipid panel. Your doctor reviews it, tells you everything looks good, and you leave.
Here is the problem: these standard panels were designed to detect established disease, not emerging dysfunction. By the time your fasting glucose crosses 100, you may have had insulin resistance for a decade. By the time your TSH hits 5.0, you may have had thyroid antibodies destroying your gland for years. By the time your LDL is flagged, you may have had elevated ApoB-carrying particles damaging your vessels for a decade.
The labs I am about to describe are not exotic. They are available at any commercial laboratory. They are well-validated by research. And for the most part, they are just not ordered because they fall outside the standard checkup template. That needs to change.
The Essential Labs Your Doctor Should Be Running
1. Fasting Insulin
Why it matters: Fasting insulin is the earliest marker of metabolic dysfunction — it rises years before fasting glucose does. Insulin resistance is the upstream driver of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, PCOS, and accelerated aging.
What standard panels include instead: Fasting glucose only. This catches the problem after the horse has left the barn.
Optimal range: 2-6 uIU/mL (functional). Conventional upper limit is 24.9, which is already advanced insulin resistance.
What I tell my patients: If I could order only one test to predict metabolic health over the next decade, it would be fasting insulin. Most doctors never order it.
2. hs-CRP (High-Sensitivity C-Reactive Protein)
Why it matters: hs-CRP is a non-specific marker of systemic inflammation. Elevated hs-CRP predicts cardiovascular events independently of cholesterol, and in chronic illness patients, it tracks inflammatory burden from infections, autoimmunity, and environmental exposures.
What standard panels include instead: Nothing. Standard CRP may be ordered but has a higher detection threshold. hs-CRP is specific enough to detect low-grade chronic inflammation.
Optimal range: Below 1.0 mg/L. Between 1.0-3.0 indicates moderate cardiovascular risk and chronic inflammation. Above 3.0 indicates high risk or active inflammatory process.
Clinical significance: In Lyme and post-COVID patients, hs-CRP helps me track treatment response. A dropping hs-CRP alongside clinical improvement confirms that we are reducing the inflammatory driver, not just masking symptoms.
3. Full Thyroid Panel
Why it matters: TSH alone misses several important thyroid dysfunction patterns. A “normal” TSH does not rule out autoimmune thyroid disease, T4-to-T3 conversion problems, or reverse T3 elevation.
What standard panels include: TSH only. Sometimes free T4.
What to request:
- TSH (pituitary signal to thyroid)
- Free T3 (the active hormone — this is what cells actually use)
- Free T4 (the storage form that converts to T3)
- TPO antibodies (thyroid peroxidase — the primary autoimmune thyroid marker)
- Thyroglobulin antibodies (second autoimmune marker)
- Reverse T3 (optional but valuable in chronic illness — an inactive form that competes with T3)
What I see in practice: At least once a week, I find a patient with “normal” TSH, normal T4, low free T3, and elevated TPO antibodies. Their conventional doctor told them their thyroid was fine. It is not fine. They have Hashimoto’s thyroiditis with impaired T4-to-T3 conversion — entirely missed by TSH alone.
4. Homocysteine
Why it matters: Homocysteine is a marker of methylation efficiency. Elevated homocysteine indicates problems in the methylation pathway — which affects detoxification, neurotransmitter production, DNA repair, and cardiovascular health.
What standard panels include: Nothing related to methylation.
Optimal range: Below 8 umol/L. Functional versus conventional ranges differ significantly here — conventional labs flag at 15, but risk increases above 8-10.
Clinical significance: In chronic illness patients, elevated homocysteine often points to B12 deficiency, folate deficiency, or MTHFR-related methylation impairment. These are correctable with targeted supplementation — but only if you know to look.
5. ApoB (Apolipoprotein B)
Why it matters: ApoB is the single best blood marker for cardiovascular risk. Every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) carries exactly one ApoB molecule. ApoB counts the number of particles that can penetrate the arterial wall — which is what matters for atherosclerosis.
What standard panels include: LDL-C (LDL cholesterol), which measures the cholesterol mass carried by LDL particles. The problem: two patients with the same LDL-C can have dramatically different numbers of LDL particles. The one with more particles (higher ApoB) has more risk, regardless of the LDL-C number.
Optimal range: Below 90 mg/dL for average risk. Below 60-70 mg/dL for high risk.
What I tell my patients: LDL cholesterol tells you how much cholesterol is in the LDL compartment. ApoB tells you how many atherogenic particles are in your blood. The particle count is what determines risk. This is not controversial — the European Atherosclerosis Society and Canadian Cardiovascular Society both recommend ApoB as the primary lipid target.
6. Vitamin D (25-Hydroxyvitamin D)
Why it matters: Vitamin D is a hormone precursor that regulates immune function, bone health, mood, and inflammation. Deficiency is epidemic (40-60% of adults in northern latitudes) and directly relevant to chronic illness — low vitamin D impairs immune response to infections and increases autoimmune risk.
What standard panels include: Often nothing. Some doctors order it, many do not.
Optimal range: 50-80 ng/mL (functional). Conventional “sufficient” starts at 30, which is insufficient for optimal immune function.
7. Ferritin
Why it matters: Ferritin is the body’s iron storage protein. Low ferritin causes fatigue, brain fog, hair loss, and exercise intolerance long before anemia develops. It is the most common missed cause of fatigue in premenopausal women.
What standard panels include: CBC with hemoglobin — which only catches iron deficiency once anemia develops. Ferritin catches the depletion stage, which can be symptomatic at levels below 30-50 ng/mL.
Optimal range: 50-150 ng/mL for women, 50-200 ng/mL for men.
8. DHEA-S (Dehydroepiandrosterone Sulfate)
Why it matters: DHEA-S is the most abundant circulating steroid hormone and a precursor to both testosterone and estrogen. It declines significantly with age and drops precipitously during chronic illness and prolonged stress. Low DHEA-S correlates with fatigue, immune dysfunction, reduced recovery, and accelerated aging.
What standard panels include: Nothing related to adrenal function.
Optimal range: Age-dependent, but generally targeting the upper third of the age-adjusted reference range.
Additional Tests for Specific Situations
For Chronic Illness Patients (Lyme, Post-COVID, CFS)
- NK cell function: Measures immune surveillance capacity
- Lymphocyte subsets: T-cell, B-cell, NK cell quantification
- CD57: Debated but used as a Lyme treatment response marker
- Organic acids test (OAT): Mitochondrial function, neurotransmitter metabolites, yeast/bacterial markers
For Cardiovascular Risk Assessment
- Lp(a): Genetic lipoprotein risk factor (test once — it does not change)
- Oxidized LDL: Direct measure of atherogenic damage
- Fibrinogen: Clotting risk and inflammation
For Hormonal Assessment
- Full sex hormone panel: Testosterone (total and free), estradiol, progesterone, SHBG
- Cortisol (morning): Adrenal function baseline
- IGF-1: Growth hormone axis assessment
The Evidence
What We Know (Human Data)
Each of these markers has substantial research supporting its clinical utility:
- Fasting insulin: The EGIR and multiple epidemiological studies define insulin resistance at levels well below the conventional lab upper limit [1]
- hs-CRP: The JUPITER trial demonstrated that statin benefit in primary prevention was driven by inflammation (hs-CRP) at least as much as by cholesterol reduction [2]
- ApoB: Meta-analyses by Sniderman et al. consistently show ApoB outperforms LDL-C as a cardiovascular risk predictor
- Thyroid antibodies: The NHANES III data show that 10-12% of the US population has elevated TPO antibodies, most of whom have “normal” TSH
What I See in Practice
In our hospital, every new patient receives the comprehensive panel described above. The most common finding: patients who have been told “everything is normal” for years have 3-5 suboptimal markers that collectively explain their symptoms and point to early disease processes that are still reversible.
What I tell my patients: the standard blood panel is like checking the oil and tire pressure on a car. Important, but it does not tell you about the transmission, the brakes, the battery, or the engine health. The functional panel checks the whole vehicle.
Practical Application
How to Request These Tests
- Bring a list to your appointment. Write down the specific tests you want. Hand it to your doctor.
- Explain your rationale. “I am interested in early detection of insulin resistance, thyroid autoimmunity, and cardiovascular risk beyond what the standard panel shows.”
- Insurance considerations: Most of these tests are covered by insurance when ordered with an appropriate diagnostic code (fatigue, screening, family history). hs-CRP, ApoB, and thyroid antibodies are standard lab offerings.
- Direct-to-consumer options: If your doctor will not order them, services like Quest, LabCorp, and specialty panels allow you to order blood work directly (in most US states).
- Frequency: These do not all need to be repeated annually. Fasting insulin, hs-CRP, and vitamin D every 6-12 months. TPO antibodies and Lp(a) once (or rarely). ApoB annually if actively managing lipids.
Interpreting Your Results
Compare your results to both conventional and functional ranges. Look for:
- Values in the “normal” range but at the high or low extreme
- Markers trending in the wrong direction over time
- Combinations of suboptimal values that create a pattern (e.g., high insulin + high hs-CRP + high fasting glucose = metabolic syndrome brewing)
Safety and Considerations
Blood testing carries minimal risk — a needle stick and occasional bruising. The main consideration is avoiding over-testing and over-treatment. Not every marker needs to be optimized to the exact center of the functional range. The goal is to identify meaningful dysfunction and trend toward optimal, not to chase lab perfection.
Cost is a legitimate consideration. For patients paying out of pocket, prioritize: fasting insulin, hs-CRP, full thyroid panel, vitamin D, and ferritin. These five additions to a standard panel provide the highest yield per dollar.
The Bottom Line
The standard blood panel catches established disease. The functional medicine panel catches emerging dysfunction — years earlier, when intervention is easier, cheaper, and more effective. The labs described here are not exotic or unvalidated. They are well-researched markers that most doctors simply do not include in routine screening. Requesting them is not being difficult. It is being thorough. And thoroughness is what catches the problems that “everything looks normal” misses.
References
- Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607. PMID: 3056758.
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine. 2008;359(21):2195-2207. PMID: 18997196.
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology. 2019;4(12):1287-1295. PMID: 31642874.
- Hollowell JG, et al. Serum TSH, T4, and thyroid antibodies in the United States population. Journal of Clinical Endocrinology and Metabolism. 2002;87(2):489-499. PMID: 11836274.
